Go to the About Us section
Go to the Courses section
Go to the Research section
Go to the Specialist Services & Consultancy section
Go to the Outreach section
Go to the New Students section
You can find details about all the staff in the department below.
return to full list
Department of Biological and Medical Sciences
Faculty of Health and Life Sciences
Nigel was involved with productive collaborations resulting in co-authored papers with research groups in Japan, the USA, Finland, New Zealand, Austria, Denmark, the Netherlands, France, Australia, Argentina and other countries. He is co-author on 320 refereed scientific publications listed in the Web of Science database. Seventeen of these papers have been cited more than 100 times and the most cited paper has in excess of 700 citations. For publications in the period 1993-2003, he was rated among the top 0.1% for highly cited authors in clinical medicine. A selection of his papers and other publications can be seen below.
Prof. Groome continues to be involved in the University through supporting the PhD research programme in the faculty; since 2008 the University has awarded the Nigel Groome PhD studentships within the Faculty of Health and Life Sciences which are funded by the royalty income from his inhibin patented technology. In addition, one of Nigel’s former PhD students funds the Al-Qahtani/Groome Prize which is awarded in January each year to a postgraduate student at the postgraduate symposium.
Real-world applications of research outcomes:
The assays are now widely used in clinical settings, providing routine tools for prenatal screening and infertility investigations in laboratories worldwide; 70% of pregnancies in the US are screened using the quad or integrated tests which use inhibin A. The greatest impact of Groome’s work has been in providing a greater accuracy in pre-natal Down’s syndrome screening with an estimated 3 million pregnancies screened annually in the US and approximately 120,000 annually in the UK. Other clinical applications include;
The immunoassays were initially commercialised by Brookes’ first spin-out company, Oxford Bio-Innovation, which was established in 1998. This was sold to a US diagnostic company in 2000 for around £1million. The patents on the technology are now licensed for use by Beckman Coulter, and annual royalty income generated for the University from the licensing totalled approximately £5million between 2008-2012.